Biotech and Pharmaceuticals
Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
The Eli Lilly & Co. logo at the company’s Digital Health Innovation Hub facility in Singapore, on Thursday, Nov. 14, 2024. Ore Huiying | Bloomberg | Getty Images Eli Lilly cut its revenue guidance on Tuesday as it said demand for its weight loss and diabetes drugs would not meet its lofty expectations. The drugmaker’s […]
Read More
Eli Lilly CEO expects new weight loss pill to be approved next year
David Ricks, CEO, Eli Lilly Scott Mlyn | CNBC Eli Lilly expects its experimental weight loss pill will get approved as soon as early next year, CEO David Ricks told Bloomberg TV on Monday. The company is set to release key late-stage trial data on the drug, orforglipron, by the middle of this year. Eli […]
Read More
Eli Lilly to buy Scorpion Therapeutics’ cancer therapy for up to $2.5 billion
A sign with the company logo outside the headquarters of Eli Lilly and Company in Indianapolis, Indiana, March 17, 2024. Scott Olson | Getty Images Eli Lilly said on Monday it plans to buy Scorpion Therapeutics’ experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of cancer treatments. The company […]
Read More
Moderna stock plunges 18% after company lowers 2025 sales forecast by $1 billion
The Moderna Inc. headquarters in Cambridge, Massachusetts, US, on Tuesday, March 26, 2024. Adam Glanzman | Bloomberg | Getty Images Moderna on Monday lowered its 2025 sales guidance by roughly $1 billion due to a few potential headwinds later this year, as the biotech company continues to cut costs and expand its portfolio. Moderna now […]
Read More
Walgreens results top estimates as drugstore chain works to slash costs
People walk by a Walgreens on Nov. 3, 2024 in Brookline, Massachusetts. Danielle DeVries | CNBC Walgreens on Friday reported fiscal first-quarter earnings and revenue that topped expectations, as it shutters stores and cuts other costs to steer itself out of a rough spot. Here’s what Walgreens reported for the three-month period ended Nov. 30 […]
Read More
Medicare can now cover Eli Lilly’s Zepbound for sleep apnea, CMS says
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters Medicare drug plans can now cover Eli Lilly‘s blockbuster obesity drug Zepbound for obstructive sleep apnea, CNBC confirmed on Wednesday. That opens the door for broader access to Zepbound, which is […]
Read More
Eli Lilly’s lead in the obesity race has grown. Its recent stock performance says otherwise
Eli Lilly investors have received some really good news in recent months with a notable exception of how the stock has performed. Shares of Eli Lilly entered Wednesday’s session off nearly 9% since the Oct. 30 close, the day that the drugmaker’s messy third-quarter earnings report sent the stock down 6%. Zoom out further to […]
Read More
Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market
Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, August 29, 2020. Andrew Kelly | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The U.S. Food and […]
Read More
J&J says its lung cancer drug combination keeps people alive longer
Niels Wenstedt | Getty Images Johnson & Johnson on Tuesday said its lung cancer regimen keeps people alive for at least a year longer than AstraZeneca‘s Tagrisso, the go-to drug for a certain type of lung cancer. J&J in a statement said its drugs – Rybrevant and Lazcluze – showed a statistically significant and clinically […]
Read More
These innovative biotech stocks have a good chance of breaking out in 2025
Trends may be shifting in favor of biotech stocks in 2025 after several years of poor performance, but it would still be wise to place your bets carefully on some of the most innovative names. “We’re still optimistic on the outlook for biotech,” said Stacey Sears, senior vice president and portfolio manager at Emerald Advisors, […]
Read More